Arno Therapeutics, Inc. (ARNI)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Arno Therapeutics, Inc. (ARNI) trades at $0.00 with AI Score 48/100 (Weak). Arno Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for cancer and other life-threatening diseases. Market cap: 10K, Sector: Healthcare.
Last analyzed: Mar 15, 2026Arno Therapeutics, Inc. (ARNI) Healthcare & Pipeline Overview
Arno Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer treatments, with a focus on hormone blockers and orally available therapies, aiming to address unmet medical needs in oncology.
Investment Thesis
Arno Therapeutics, Inc. presents a unique investment thesis driven by its focused pipeline of cancer therapies, particularly Onapristone, AR-12, and AR-42. The company is currently in the early stages of clinical development, with Onapristone in Phase I/II studies, which could lead to significant milestones and potential partnerships upon successful outcomes. The market for cancer therapeutics is projected to grow substantially, driven by rising incidences of cancer and increasing demand for innovative treatments. The company's collaborations with established institutions may enhance its research capabilities and accelerate development timelines. However, investors may want to evaluate the inherent risks associated with clinical trials, including regulatory hurdles and the potential for unfavorable results. Overall, Arno's strategic focus on niche oncology markets positions it for potential growth in a rapidly evolving industry.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap: $0.00B indicates a pre-revenue stage company with potential for growth.
- P/E Ratio of -0.00 reflects ongoing investments in R&D without current profitability.
- Beta of 1.55 suggests higher volatility compared to the broader market, typical for biotech firms.
- No dividend yield as the company reinvests in its clinical development pipeline.
- Small workforce of 4 employees indicates a lean operational model focused on R&D.
Competitors & Peers
Strengths
- Innovative pipeline of cancer therapies addressing significant medical needs.
- Strategic partnerships enhancing research capabilities and market reach.
- Focused approach on niche oncology markets with growth potential.
Weaknesses
- Limited financial resources due to pre-revenue status.
- Small workforce may limit operational capacity and scalability.
- Dependence on successful clinical trial outcomes for future growth.
Catalysts
- Upcoming: Results from Phase I/II clinical studies for Onapristone could significantly impact the company's valuation and partnership opportunities.
- Ongoing: Development of AR-12 and AR-42 as potential therapies for various cancers, with ongoing clinical trials.
- Upcoming: Potential announcements of new partnerships or collaborations with larger pharmaceutical companies to enhance research capabilities.
Risks
- Ongoing: Dependence on the success of clinical trials, which may not yield favorable results.
- Potential: Regulatory challenges that could delay the approval of drug candidates.
- Ongoing: Market competition from established biotechnology firms with more resources.
Growth Opportunities
- Growth opportunity 1: Onapristone's Phase I/II clinical studies could unlock a significant market, as the global breast cancer therapeutics market is expected to reach $30 billion by 2026. Successful results may lead to partnerships with larger pharmaceutical companies, enhancing Arno's market presence and financial stability.
- Growth opportunity 2: The increasing prevalence of advanced castration-resistant prostate cancer presents a substantial opportunity for Onapristone. The prostate cancer treatment market is projected to grow at a CAGR of 8% over the next five years, providing a favorable environment for Arno's innovative therapies.
- Growth opportunity 3: AR-12's completion of Phase I trials for solid tumors and hematological malignancies positions it well within a market projected to reach $50 billion by 2026. This growth is fueled by rising demand for effective cancer treatments, particularly in underserved patient populations.
- Growth opportunity 4: The collaboration with Leica Biosystems Newcastle Ltd. for co-development may enhance Arno's research capabilities and expedite the development of its therapies, potentially leading to faster market entry and revenue generation.
- Growth opportunity 5: The expansion of pre-clinical studies for AR-12 targeting anti-microbial applications could open new revenue streams, tapping into the growing market for antimicrobial therapies, which is expected to reach $60 billion by 2025.
Opportunities
- Growing global cancer therapeutics market presents expansion potential.
- Potential for partnerships with larger pharmaceutical companies for commercialization.
- Exploration of new therapeutic areas for existing drug candidates.
Threats
- High competition in the biotechnology sector from established players.
- Regulatory hurdles and potential delays in clinical trial approvals.
- Market volatility affecting funding and investment opportunities.
Competitive Advantages
- Strong focus on niche oncology markets with high unmet medical needs.
- Established partnerships with reputable academic and pharmaceutical institutions.
- Innovative drug candidates with unique mechanisms of action.
- Expertise in navigating complex regulatory environments for drug development.
- Lean operational model allowing for efficient resource allocation.
About ARNI
Founded in Flemington, New Jersey, Arno Therapeutics, Inc. is a biopharmaceutical company that specializes in the development of innovative therapies for cancer and other life-threatening diseases. The company has made significant strides in its product development pipeline, which includes Onapristone, a type 1 anti-progestin hormone blocker currently in Phase I/II clinical studies targeting breast, endometrial, and other solid tumors in post-menopausal women, as well as advanced castration-resistant prostate cancer in men. Additionally, Arno is advancing AR-12, an orally available cancer treatment that has completed Phase I clinical studies for solid tumors and hematological malignancies, and is also in pre-clinical studies for various anti-microbial targets. Another promising candidate, AR-42, is a novel orally available cancer therapy currently in Phase I investigator-initiated clinical studies for hematological malignancies and solid tumors. The company has established strategic partnerships through license agreements with Invivis Pharmaceuticals, the Regents of the University of Minnesota, and the Ohio State University Innovation Foundation, along with a co-development agreement with Leica Biosystems Newcastle Ltd. Despite its small team of four employees, Arno Therapeutics is committed to addressing critical healthcare challenges through innovative biopharmaceutical solutions.
What They Do
- Develop innovative treatments for cancer and other life-threatening diseases.
- Conduct clinical trials to evaluate the efficacy and safety of their drug candidates.
- Engage in strategic partnerships and collaborations with academic and pharmaceutical institutions.
- Focus on hormone blockers and orally available cancer therapies.
- Advance multiple drug candidates through various stages of clinical development.
- Explore new applications for existing therapies in different therapeutic areas.
Business Model
- Generate revenue through partnerships and collaborations with larger pharmaceutical companies.
- Potential future revenue from successful drug commercialization after regulatory approval.
- Leverage research and development investments to create innovative therapies.
- Utilize clinical trial results to attract investment and funding for further development.
- Engage in licensing agreements for proprietary technologies and drug candidates.
Industry Context
The biotechnology industry is characterized by rapid advancements in drug development and a strong focus on personalized medicine. The global cancer therapeutics market is projected to reach approximately $200 billion by 2026, driven by increasing cancer prevalence and demand for innovative therapies. Arno Therapeutics operates in a competitive landscape with peers such as AMPE, BTTX, BXRXQ, CALA, and IVBT, each working on novel treatments to address significant unmet medical needs. The ongoing research and development efforts in oncology present both opportunities and challenges for emerging companies like Arno.
Key Customers
- Healthcare providers seeking innovative cancer treatments for their patients.
- Pharmaceutical companies interested in partnerships for drug development.
- Investors looking for opportunities in the biotechnology sector.
- Research institutions collaborating on clinical studies and drug development.
- Patients in need of advanced therapies for cancer and life-threatening diseases.
Financials
Chart & Info
Arno Therapeutics, Inc. (ARNI) stock price: $0.00 (+0.00, +0.00%)
Latest News
-
indie Semiconductor, Inc. 2025 Q4 - Results - Earnings Call Presentation
All Articles on Seeking Alpha · Feb 20, 2026
-
Inseego Corp. 2025 Q4 - Results - Earnings Call Presentation
All Articles on Seeking Alpha · Feb 20, 2026
-
Altus Group Limited (AIF:CA) Q4 2025 Earnings Call Transcript
All Articles on Seeking Alpha · Feb 20, 2026
-
Earnings call transcript: Boom Logistics H1 2026 shows robust growth
All News · Feb 20, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ARNI.
Price Targets
Wall Street price target analysis for ARNI.
MoonshotScore
What does this score mean?
The MoonshotScore rates ARNI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
indie Semiconductor, Inc. 2025 Q4 - Results - Earnings Call Presentation
Inseego Corp. 2025 Q4 - Results - Earnings Call Presentation
Altus Group Limited (AIF:CA) Q4 2025 Earnings Call Transcript
Earnings call transcript: Boom Logistics H1 2026 shows robust growth
Leadership: David M. Tanen
CEO
David M. Tanen has extensive experience in the biopharmaceutical industry, having held various leadership roles in both public and private companies. He has a strong background in drug development and commercialization, with a focus on oncology. Tanen has been instrumental in guiding Arno Therapeutics through its strategic initiatives and clinical development programs.
Track Record: Under David M. Tanen's leadership, Arno Therapeutics has advanced its product pipeline significantly, securing key partnerships and collaborations that enhance its research capabilities. His strategic vision has positioned the company to capitalize on emerging opportunities in the oncology market.
ARNI OTC Market Information
The OTC Other tier includes companies that do not meet the criteria for higher tiers like OTCQX or OTCQB, indicating less stringent reporting requirements. This tier typically has lower liquidity and visibility compared to stocks listed on major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Lower visibility and investor interest compared to larger, listed companies.
- Potential for higher volatility due to lower trading volumes.
- Lack of comprehensive financial disclosures may lead to information asymmetry.
- Verify the company's clinical trial progress and results.
- Assess the strength and terms of existing partnerships.
- Review the management team's experience and track record.
- Evaluate the competitive landscape and market potential for their therapies.
- Investigate any regulatory hurdles or pending approvals.
- Established partnerships with reputable institutions.
- Active participation in clinical trials and research initiatives.
- Transparent communication regarding clinical development progress.
ARNI Healthcare Stock FAQ
What does Arno Therapeutics, Inc. do?
Arno Therapeutics, Inc. focuses on developing innovative biopharmaceutical products aimed at treating cancer and other life-threatening diseases. Their key products include Onapristone, AR-12, and AR-42, which are currently in various stages of clinical development targeting specific cancer types.
What do analysts say about ARNI stock?
Analysts generally view ARNI stock as a high-risk investment due to its pre-revenue status and reliance on clinical trial outcomes. The company's innovative pipeline and strategic partnerships are seen as positive indicators, but the lack of current revenue and financial disclosures raises concerns among investors.
What are the main risks for ARNI?
Key risks for Arno Therapeutics, Inc. include the inherent uncertainties of clinical trials, which may not result in successful outcomes, regulatory hurdles that could delay drug approvals, and intense competition from larger biotechnology firms that may have more resources and established market presence.
What are the key factors to evaluate for ARNI?
Arno Therapeutics, Inc. (ARNI) currently holds an AI score of 48/100, indicating low score. Key strength: Innovative pipeline of cancer therapies addressing significant medical needs.. Primary risk to monitor: Ongoing: Dependence on the success of clinical trials, which may not yield favorable results.. This is not financial advice.
How frequently does ARNI data refresh on this page?
ARNI prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ARNI's recent stock price performance?
Recent price movement in Arno Therapeutics, Inc. (ARNI) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative pipeline of cancer therapies addressing significant medical needs.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ARNI overvalued or undervalued right now?
Determining whether Arno Therapeutics, Inc. (ARNI) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ARNI?
Before investing in Arno Therapeutics, Inc. (ARNI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available due to OTC classification and pre-revenue status.